Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Roche Hldg Ltd Spons (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 218,229,744
  • Shares Outstanding, K 6,815,420
  • Annual Sales, $ 53,441 M
  • Annual Income, $ 9,723 M
  • 36-Month Beta 0.63
  • Price/Sales 4.40
  • Price/Cash Flow 17.81
  • Price/Book 8.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/17
  • Annual Dividend & Yield 0.85 (2.64%)
  • Most Recent Dividend 0.84 on 03/15/17
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.2700 +2.40%
on 08/23/17
32.2900 -0.84%
on 09/08/17
+0.5600 (+1.78%)
since 08/22/17
3-Month
30.7000 +4.30%
on 07/11/17
32.8200 -2.44%
on 06/28/17
-0.2800 (-0.87%)
since 06/22/17
52-Week
25.2500 +26.81%
on 12/08/16
36.8200 -13.04%
on 04/28/17
+0.4750 (+1.51%)
since 09/22/16

Most Recent Stories

More News
Cancer Space Update: Mixed Week for Pfizer, Roche Falters

Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

MRK : 65.13 (-0.72%)
KPTI : 10.63 (+1.43%)
TSRO : 119.04 (+0.31%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

JNJ : 131.39 (-0.27%)
SUPN : 39.00 (-1.02%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

URGN : 30.49 (+3.32%)
ABEO : 14.95 (-7.72%)
CLSD : 8.30 (+1.84%)
RETA : 31.75 (+0.41%)
NVS : 86.16 (+1.44%)
GILD : 83.27 (+0.79%)
RHHBY : 32.0200 (-0.06%)
KITE : 179.30 (-0.04%)
AMGN : 185.76 (-0.47%)
How is the Age-Related Macular Degeneration Space Faring Now?

The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.

AGN : 204.65 (+0.98%)
OPHT : 2.69 (unch)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
REGN : 432.72 (-0.17%)
Mylan Down 24% Year to Date: What's Troubling the Stock?

Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.

MYL : 31.30 (+0.19%)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Novartis Poised to Grow on Oncology Portfolio & Biosimilars

Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ALXN : 142.82 (-0.07%)
Roche (RHHBY) Announces Positive Data on Leukemia Drug

Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.

CELG : 143.89 (+0.08%)
MRK : 65.13 (-0.72%)
ABBV : 87.48 (+0.08%)
RHHBY : 32.0200 (-0.06%)
Novartis Announces Positive Data on Urticaria Drug Xolair

Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ADRO : 10.80 (-1.82%)
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA

Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.

CELG : 143.89 (+0.08%)
MRK : 65.13 (-0.72%)
RHHBY : 32.0200 (-0.06%)
BMY : 63.36 (+0.05%)
Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared to Bendamustine Plus Rituxan

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MURANO study, which evaluated Venclexta(TM) (venetoclax) in combination with Rituxan(R)...

RHHBY : 32.0200 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

See More

Support & Resistance

2nd Resistance Point 32.1667
1st Resistance Point 32.0933
Last Price 32.0200
1st Support Level 31.9733
2nd Support Level 31.9267

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.